ATO was administered for 28 days every 8 weeks and ATRA was administered for 2 weeks ... with no or minimal exposure to conventional DNA-damaging chemotherapy in the majority of patients.

TD Cowen analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) yesterday. The company’s shares closed last Friday at $6.90. See what stocks are ...

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $1.19 per share versus the Zacks Consensus Estimate of a loss of $3.82. This compares to loss of $14 per share a year ago.

In 2003, Pankaj Malhotra, Head, Department of Clinical Hematology, PGIMER, introduced arsenic trioxide (ATO) and all-trans ...

How did you improve the administration of leukaemia treatment? The use of all-trans retinoic acid (ATRA) plus chemotherapy has been the standard therapy for APL, and has improved cure rates to ...

ATRA opened at $6.91 on Wednesday. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $23.44. The stock has a market cap of $39.80 million, a P/E ratio of -0.27 and a beta of ...

The introduction of all-trans retinoic acid in 1985 combined with anthracycline-based chemotherapy has revolutionized the prognosis of acute promyelocytic leukemia (APL) with current complete ...